Daré Bioscience, Inc.
DARE
$2.88
-$0.04-1.37%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -99.08% | -99.65% | 88.13% | -- | -71.83% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -99.08% | -99.65% | 88.13% | -- | -71.83% |
| Cost of Revenue | -33.65% | -18.51% | -17.15% | -17.15% | -17.15% |
| Gross Profit | 25.33% | 6.41% | 20.76% | 26.57% | -10.00% |
| SG&A Expenses | -21.78% | -23.12% | -16.98% | -11.27% | -6.39% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -29.36% | -30.07% | -42.05% | -27.37% | -24.59% |
| Operating Income | 22.44% | 23.71% | 45.15% | 34.34% | 9.53% |
| Income Before Tax | 94.19% | 86.56% | 91.22% | 81.89% | 5.61% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 94.19% | 86.56% | 91.22% | 81.89% | 5.61% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 94.19% | 86.56% | 91.22% | 81.89% | 5.61% |
| EBIT | 22.44% | 23.71% | 45.15% | 34.34% | 9.53% |
| EBITDA | 23.01% | 23.75% | 45.21% | 34.40% | 9.57% |
| EPS Basic | 94.68% | 87.68% | 91.08% | 81.37% | 13.53% |
| Normalized Basic EPS | 92.67% | 85.77% | 91.55% | 81.85% | 14.15% |
| EPS Diluted | 94.22% | 87.27% | 90.76% | 81.05% | 13.38% |
| Normalized Diluted EPS | 92.36% | 85.48% | 91.35% | 81.65% | 14.16% |
| Average Basic Shares Outstanding | 10.72% | 14.14% | 13.58% | 12.32% | 8.58% |
| Average Diluted Shares Outstanding | 10.93% | 14.36% | 13.81% | 12.55% | 8.35% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |